ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.499
0.19%
Brent Oil
81.975
-0.18%
Bitcoin
66,198.24
-0.66%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Athenex Inc (ATNX)

  7. Athenex Inc (ATNX) Noticias

ATNX

Athenex (ATNX)

Athenex Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATNX
FechaHoraFuenteTítuloSímboloCompañía
23/05/202307:04Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:ATNXAthenex Inc
22/05/202315:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATNXAthenex Inc
14/05/202310:15GlobeNewswire Inc.Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ProcessNASDAQ:ATNXAthenex Inc
08/05/202315:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATNXAthenex Inc
01/05/202312:00PR Newswire (US)Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCONASDAQ:ATNXAthenex Inc
28/04/202307:11Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ATNXAthenex Inc
20/03/202313:07Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ATNXAthenex Inc
20/03/202307:00GlobeNewswire Inc.Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business UpdateNASDAQ:ATNXAthenex Inc
14/02/202315:25Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ATNXAthenex Inc
14/02/202307:00GlobeNewswire Inc.Athenex Announces a Reverse Stock SplitNASDAQ:ATNXAthenex Inc
02/02/202316:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ATNXAthenex Inc
03/01/202307:00GlobeNewswire Inc.Athenex Announces MHRA Decision on Oral PaclitaxelNASDAQ:ATNXAthenex Inc
20/12/202207:15GlobeNewswire Inc.Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast CancerNASDAQ:ATNXAthenex Inc
16/12/202207:00GlobeNewswire Inc.Athenex Exits 503B Sterile Compounding BusinessNASDAQ:ATNXAthenex Inc
09/12/202215:32Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ATNXAthenex Inc
22/11/202209:30GlobeNewswire Inc.Athenex Announces Positive Results of Special Stockholder MeetingNASDAQ:ATNXAthenex Inc
21/11/202207:00GlobeNewswire Inc.Athenex Announces Closing of the Sale of its China API BusinessNASDAQ:ATNXAthenex Inc
06/11/202221:26TipRanksSVB Securities Sticks to Their Hold Rating for Athenex (ATNX)NASDAQ:ATNXAthenex Inc
03/11/202209:56Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATNXAthenex Inc
03/11/202206:05GlobeNewswire Inc.Athenex Announces Receipt of Positive Nasdaq Listing DeterminationNASDAQ:ATNXAthenex Inc
03/11/202206:00GlobeNewswire Inc.Athenex Provides Third Quarter 2022 Financial Results and Business UpdateNASDAQ:ATNXAthenex Inc
11/10/202208:15GlobeNewswire Inc.Athenex Files Definitive Proxy Statement for Special Stockholder MeetingNASDAQ:ATNXAthenex Inc
11/10/202207:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ATNXAthenex Inc
12/08/202214:56Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ATNXAthenex Inc
11/08/202203:21GlobeNewswire Inc.Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and WarrantsNASDAQ:ATNXAthenex Inc
10/08/202215:01GlobeNewswire Inc.Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and WarrantsNASDAQ:ATNXAthenex Inc
05/08/202203:33TipRanksHere’s Why Athenex Shares Surged 70%NASDAQ:ATNXAthenex Inc
31/07/202222:31TipRanksSVB Securities Reiterates a Hold Rating on Athenex (ATNX)NASDAQ:ATNXAthenex Inc
28/07/202206:00GlobeNewswire Inc.Athenex Provides Second Quarter 2022 Financial Results and Business UpdateNASDAQ:ATNXAthenex Inc
25/07/202209:00GlobeNewswire Inc.Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical OncologyNASDAQ:ATNXAthenex Inc
 Showing the most relevant articles for your search:NASDAQ:ATNX

Su Consulta Reciente

CCOM
US500
US 500
FX
USDMXN
US Dollar vs MXN
AMEX
XLV
Health Care Select Sector
PM
XAUUSD
Gold vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AMZN
Amazon.com
NYSE
BAC
Bank of America
CCOM
OILBRENT
Brent Oil
SPI
SP500
S&P 500
NYSE
VZ
Verizon Communications
CCOM
SILVER
SILVER
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
CVX
Chevron
FX
EURUSD
Euro vs US Dollar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados